# Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Canonical URL: https://biopharmsignal.com/news/MCRB/seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic-candidate-for-inflammatory-bowel-disease
Ticker: MCRB
Company: Seres Therapeutics
Source: Seres Therapeutics
Published: 2026-05-04 11:00 EST
Original Source URL: https://ir.serestherapeutics.com
## Summary

Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification Presentation selected for DDW

## Article Body
Data highlight both SER-603’s rational design that targets microbial functions linked to mucosal healing and gastrointestinal inflammation in IBD, as well as the advancement of microbiome-based biomarkers that inform response to biologics and patient stratification Presentation selected for DDW
## Recent Company News
- 2026-05-12 11:00 EST — [Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Seres Therapeutics
- 2026-05-05 11:00 EST — [Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/MCRB/seres-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-updates) — Source: Seres Therapeutics
- 2026-05-04 11:00 EST — [Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease](https://biopharmsignal.com/news/MCRB/seres-therapeutics-presents-preclinical-data-at-digestive-disease-week-ddw-2026-supporting-ser-603-a-next-generation-cultivated-live-biotherapeutic-candidate-for-inflammatory-bowel-disease) — Source: Seres Therapeutics
- 2026-04-20 11:00 EST — [Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026](https://biopharmsignal.com/news/MCRB/seres-therapeutics-showcases-ser-155-data-and-live-biotherapeutic-insights-at-escmid-global-2026) — Source: Seres Therapeutics
- 2026-04-09 11:00 EST — [Seres Therapeutics to Present at CARB-X Investor Day](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-present-at-carb-x-investor-day) — Source: Seres Therapeutics
## Related News
- 2026-07-22 20:15 EST — BFRG — [BullFrog AI to Participate in the BTIG Virtual Biotechnology Conference](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-the-btig-virtual-biotechnology-conference-5880a10e)
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)